TECHNOLOGY OVERVIEW

SustentoBio Inc. is a biotechnology company focused on the development and sale of immunotherapies for the companion animal market.

 

SustentoBio’s core technology centers around recombinant fusion proteins called TBX-4403 & SBX-4400 which are based on in-licensed technologies discovered during human clinical development of an analogous protein. Both TBX-4403 & SBX-4400 are able to temporarily boost the function of the immune system to better fight solid tumors and infectious disease.

TAT Protein + MYC Protein = TBX-4403 & SBX-4400

Our Key Diference_Sustento_vboth.png

TURNING UP THE IMMUNE SYSTEM

  • TAT enables TBX-4403 & SBX-4400 to penetrate the cell membrane. Once inside the cell, MYC is shuttled to the nucleus where it functions.

  • Other technologies lack this ability, so they must target receptors on the cell membrane. If there are any problems with the signaling pathways, these other treatments won't work.  Since we bypass this process, our protein works where others fail.

  • TBX-4403 & SBX-4400 are the only product with this capability.

TBX-4403 IS UNIQUE BECAUSE IT:

  • Enters the cell and modifies the cell itself, NOT the receptors on the surface of the cell.

  • Is a fusion of naturally occurring proteins and does NOT use chemicals or genetic engineering.

  • Can treat a variety of diseases, NOT just one.